Evidence map›Paper›PMID 33484949›Full record

ArticleMolecular metabolism2021

Free fatty acid receptor 4 inhibitory signaling in delta cells regulates islet hormone secretion in mice.

Marine L Croze, Marcus F Flisher, Arthur Guillaume, Caroline Tremblay, Glyn M Noguchi, Sabrina Granziera, Kevin Vivot, Vincent C Castillo, Scott A Campbell, Julien Ghislain and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. FFAR4 Deficiency Increases Necrotic Cores in Advanced Lesions of ApoEArteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Metabolic and Molecular Amplification of Insulin Secretion.Advances in anatomy, embryology, and cell biology · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Marine L CrozeMontreal Diabetes Research Center, CRCHUM, Montréal, QC, Canada.
Marcus F FlisherDepartment of Neurobiology, Physiology, and Behavior, College of Biological Sciences, University of California Davis, Davis, CA, USA.
Arthur GuillaumeMontreal Diabetes Research Center, CRCHUM, Montréal, QC, Canada.
Caroline TremblayMontreal Diabetes Research Center, CRCHUM, Montréal, QC, Canada.
Glyn M NoguchiDepartment of Neurobiology, Physiology, and Behavior, College of Biological Sciences, University of California Davis, Davis, CA, USA.
Sabrina GranzieraMontreal Diabetes Research Center, CRCHUM, Montréal, QC, Canada.
Kevin VivotMontreal Diabetes Research Center, CRCHUM, Montréal, QC, Canada.
Vincent C CastilloDepartment of Neurobiology, Physiology, and Behavior, College of Biological Sciences, University of California Davis, Davis, CA, USA.
Scott A CampbellMontreal Diabetes Research Center, CRCHUM, Montréal, QC, Canada.
Julien GhislainMontreal Diabetes Research Center, CRCHUM, Montréal, QC, Canada.
Mark O HuisingDepartment of Neurobiology, Physiology, and Behavior, College of Biological Sciences, University of California Davis, Davis, CA, USA; Department of Physiology and Membrane Biology, School of Medicine, University of California Davis, Davis, CA, USA.
Vincent PoitoutMontreal Diabetes Research Center, CRCHUM, Montréal, QC, Canada; Department of Medicine, Université de Montréal, Montréal, QC, Canada. Electronic address: vincent.poitout@umontreal.ca.
University of California, Davis · USUniversité de Montréal · CA

Funding

PARACRINE FEEDBACK BY PANCREATIC DELTA CELLS TO CONTROL GLUCAGON AND INSULIN RELEASE AND MANAGE DIABETESR01DK110276 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Mark O. Huising · 2017 to 2026
$3.9M
University of California Davis Advancing Diversity in Aging Research Scholars ProgramR25AG048787 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Keith Baar · 2015 to 2026
$3.6M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
NIA NIH HHS R25 AG048787NIDDK NIH HHS R01 DK110276NIGMS NIH HHS T32 GM099608
6 · The paper itself

Abstract

objectiveMaintenance of glucose homeostasis requires the precise regulation of hormone secretion from the endocrine pancreas. Free fatty acid receptor 4 (FFAR4/GPR120) is a G protein-coupled receptor whose activation in islets of Langerhans promotes insulin and glucagon secretion and inhibits somatostatin secretion. However, the contribution of individual islet cell types (α, β, and δ cells) to the insulinotropic and glucagonotropic effects of GPR120 remains unclear. As gpr120 mRNA is enriched in somatostatin-secreting δ cells, we hypothesized that GPR120 activation stimulates insulin and glucagon secretion via inhibition of somatostatin release.

methodsGlucose tolerance tests were performed in mice after administration of selective GPR120 agonist Compound A. Insulin, glucagon, and somatostatin secretion were measured in static incubations of isolated mouse islets in response to endogenous (ω-3 polyunsaturated fatty acids) and/or pharmacological (Compound A and AZ-13581837) GPR120 agonists. The effect of Compound A on hormone secretion was tested further in islets isolated from mice with global or somatostatin cell-specific knock-out of gpr120. Gpr120 expression was assessed in pancreatic sections by RNA in situ hybridization. Cyclic AMP (cAMP) and calcium dynamics in response to pharmacological GPR120 agonists were measured specifically in α, β, and δ cells in intact islets using cAMPER and GCaMP6 reporter mice, respectively.

resultsAcute exposure to Compound A increased glucose tolerance, circulating insulin, and glucagon levels in vivo. Endogenous and/or pharmacological GPR120 agonists reduced somatostatin secretion in isolated islets and concomitantly demonstrated dose-dependent potentiation of glucose-stimulated insulin secretion and arginine-stimulated glucagon secretion. Gpr120 was enriched in δ cells. Pharmacological GPR120 agonists reduced cAMP and calcium levels in δ cells but increased these signals in α and β cells. Compound A-mediated inhibition of somatostatin secretion was insensitive to pertussis toxin. The effect of Compound A on hormone secretion was completely absent in islets from mice with either global or somatostatin cell-specific deletion of gpr120 and partially reduced upon blockade of somatostatin receptor signaling by cyclosomatostatin.

conclusionsInhibitory GPR120 signaling in δ cells contributes to both insulin and glucagon secretion in part by mitigating somatostatin release.

Indexed as

AnimalsFatty Acids, NonesterifiedFemaleGlucagonGlucagon-Secreting CellsGlucoseGlucose Tolerance TestHomeostasisInsulinInsulin-Secreting CellsInsulin SecretionIslets of LangerhansMaleMiceMice, Inbred C57BLMice, KnockoutFatty Acids, NonesterifiedFFAR4 protein, mouseGlucagonGlucoseInsulinReceptors, G-Protein-CoupledSomatostatinFFAR4GlucagonGPR120InsulinIslet of langerhansSomatostatin

Identifiers

PMID33484949
PMCPMC7873385
OpenAlexW3125472487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.